Viewing Study NCT05815186



Ignite Creation Date: 2024-05-06 @ 6:51 PM
Last Modification Date: 2024-10-26 @ 2:56 PM
Study NCT ID: NCT05815186
Status: WITHDRAWN
Last Update Posted: 2024-03-29
First Post: 2023-04-04

Brief Title: Ladarixin With Sotorasib in Advanced NSCLC - Phase II
Sponsor: NYU Langone Health
Organization: NYU Langone Health

Study Overview

Official Title: Phase II Study of Ladarixin and Sotorasib In Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer NSCLC
Status: WITHDRAWN
Status Verified Date: 2024-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Study record has been combined with NCT05815173 Phase III study
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Study record has been combined with NCT05815173 See NCT05815173 for summary
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None